Navigation Links
NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Date:5/25/2010

PARIS, May 25, 2010 /PRNewswire/ --

- NEVO(TM), Incorporating RES TECHNOLOGY(TM), Continues to Support Excellent Safety and Efficacy Outcomes vs. the Taxus(R) Liberte(R) According to Data Presented at EuroPCR 2010

At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus(R) Liberte(R) according to new data presented today from the NEVO(TM) RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in Europe for physicians specializing in interventional cardiovascular medicine.

Through 12-month follow-up, there have been no episodes of stent thrombosis reported in the NEVO(TM) arm, whereas two such events have been reported through 12 months in patients treated with the Taxus(R) Liberte(R) stent, and a third event in this arm was reported after 13 months. Additionally there have been no cases of cardiac death or out-of-hospital myocardial infarction (MI) for patients receiving NEVO(TM).

While the trial was not powered for clinical endpoints and thus no statistically-significant differences were observed, the rates of death, MI, the need for repeat revascularization, and the occurrence of stent thrombosis numerically favored NEVO(TM) over Taxus(R) Liberte(R) to an even greater degree at 12 months than they had at six months. Similar trends were observed in the pre-defined subgroups of patients with diabetes and patients with lesion lengths less than or greater than 20 mm.

At the six-month primary endpoint of this prospective, randomized clinical trial, NEVO(TM) was reported to be superior to Taxus(R) Liberte(R) in in-stent late
'/>"/>

SOURCE Cordis Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients
2. French Physicians to Conduct 2000-Patient Study of CATANIA(TM) Coronary Stent
3. TCT 2009 to Feature vProtect(TM) Luminal Shield, a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical
4. New Insights Link Low HDL-Cholesterol and Elevated Triglycerides With Coronary Heart Disease and Microvascular Complications in Patients at Goal for LDL-Cholesterol
5. First Use in Coronary Patients of a Combined Near-Infrared Spectroscopy and Ultrasound Imaging Catheter
6. FDA has Granted HUD (Humanitarian Use Device) Designation to ITGIs Pericardium Covered Stents, Over and Under(R) and Aneugraft(R), for Treatment of Perforations and Dissections of Native Coronary Arteries and Saphenous Vein Grafts
7. Boston Scientific Launches New Coronary Imaging Catheter
8. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
9. LightLab Imaging Leads Global Advancement of Intracoronary Imaging
10. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
11. Terumo Interventional Systems Launches a Complete Line of Coronary Diagnostic Catheters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
(Date:8/27/2015)... ... ... Capital Edge Consulting , a nationwide consulting firm that specializes in ... as one of the top 5000 companies listed on the 2015 Inc. 5000 ... “It is truly an honor to be recognized as one of America’s fastest growing ...
(Date:8/27/2015)... Aug. 27, 2015  Neogen Corporation (NASDAQ: NEOG ... of United Kingdom -based Lab M ... media and diagnostic systems. Lab M ... leading provider of microbial testing and diagnostic products for ... The company currently sells into more than 70 countries ...
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
Breaking Biology Technology:VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Neogen acquires U.K.-based Lab M Holdings 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... LYNBROOK, N.Y., Sept. 11 BioSpecifics Technologies Corp. ... in class collagenase-based products, today announced that BioSpecifics, President, Tom ... Biotech Industry" Conference on Wednesday, September 16, 2009, at 9:00 ... in New York, NY. , , A ...
... September 11 , - ThromboGenics, ... ThromboGenics NV (Euronext Brussels: THR), a ... for eye,disease, vascular disease and cancer, announced today that it ... and "Licensing Deal of,the Year" awards at the Scrip Awards ...
... , , , HORSHAM, Pa., ... it received a Complete Response letter from the U.S. Food and ... DOXIL (doxorubicin HCI liposome injection) in combination ... metastatic breast cancer. , , Centocor ...
Cached Biology Technology:ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 2ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 2Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 5
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... WASHINGTON -- Scientists and engineers from around the world ... gather to discuss recent advances in optics and photonics ... of light -- affecting renewable energy and environmental research. ... Optics and Photonics Congress: Renewable Energy & the Environment, ...
... environmental consciousness, many buildings are being outfitted to "go green." ... Elizabeth Demaray, an associate professor of fine arts, is cultivating ... counteract the lack of native vegetation found in the city. ... New York,s Art in Odd Places Festival from Oct. 1-10 ...
... 25, 2011 Eighteen leading industry speakers will present ... on November 14-15, 2011 in Philadelphia. Nearly 100 IRT ... the major shift taking place in clinical trials - ... Many bio/pharmaceutical companies look to mitigate delays, ...
Cached Biology News:Space debris, more efficient LEDs, and thinner, cheaper solar cells 2Space debris, more efficient LEDs, and thinner, cheaper solar cells 3Space debris, more efficient LEDs, and thinner, cheaper solar cells 4Space debris, more efficient LEDs, and thinner, cheaper solar cells 5Rutgers professor uses lichen to help cities go green 2Rutgers professor uses lichen to help cities go green 3
... One-Step Kit is the ultimate in ... It has been specifically designed to ... Reverse-iT™ One-Step Kit combines the unique ... Thermoprime Plus DNA Polymerase to provide ...
... Protein A and Protein G bind specifically ... Protein A and Protein G conjugates are ... immunoglobulins (antibodies) and immunoglobulin subtypes from serum, ... other biological fluids. These reagents are also ...
... Receptor (AR) Competitor Assay Kits provide a ... screening potential AR ligands using fluorescence polarization ... binding domain protein tagged with His and ... fluorescent androgen ligand (Fluormone AL Green in ...
... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
Biology Products: